In our analysis of cancer-associated missense mutations, aside from the mutations in BRAF, KRAS, NRAS, PIK3CA and TP53, we identified the FGFR2 p.N549 mutation in endometrial carcinoma (2.0% in TCGA) and the CTNNB1 p.G34 mutation in gastric carcinoma (0.7% in TCGA), both of which are known activating hotspot mutations (9,58) (Supplementary Table S3). This evidence concerns the gene TP53 and cancer.